After the grand success of the CBCR 2019 with participants from all around the globe, Sciinov pleased to announce "2nd Annual Congress on Breast Cancer Research" during 07-08, September 2020 at Rome, Italy.
CBCR 2020 provides state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to international audience of academic and private physicians and researchers. CBCR 2020 is a forum to explore issues of mutual concern as well as exchange knowledge, share evidence, ideas, and generate solutions.
CBCR 2020 has its uniqueness in sessions as it covers from basic level to complex subjects discussed currently in the health sector. CBCR 2020 anticipates huge number of participants all around the globe with provoking Keynote lectures, Oral and Poster presentations, Symposium and Workshops.
CBCR 2020 will concentrate on creating opportunities to share information, efforts, and best practices for breast cancer across the lifespan by bridging the varied disciplines of education, advocacy, and clinical care, among others.
Breast Cancer- Present Perspective
Breast cancer during pregnancy
Metastatic Breast Cancer
Innovative Therapeutic Approaches in Breast Cancer
Trends in Breast cancer surgery procedures
Breast Biopsies
Immunology and Breast Cancer
Alternative and Complementary Medicine
Male Breast Cancer
Breast Cancer Nursing
Rehabilitation/Survivorship after Treatment
Breast Cancer-Clinical Trials
Breast Imaging Dosimetry
Clinical Implications of Breast Capsulectomy
Genetics of Breast Cancer
Hormone Therapies
Innovations in Breast cancer diagnosis
Biomarker study of Breast Cancer
Access to main conference sessions, exhibits, poster sessions and round table discussions
Handbook & Conference Kit
Tea / Coffee breaks, lunch during the conference days
Certificate of Presentation
Access to main conference sessions, exhibits, poster sessions and round table discussions
Handbook & Conference Kit
Tea / Coffee breaks and lunch during the conference days
Certificate of Participation
Access to main conference sessions during conference dates and
poster presentation
Handbook & Conference Kit
Tea / Coffee break and lunch during the conference days
Certificate of Presentation
Rome is a city drenched in history and Christianity.It is a city that is proud of its ancient glorious heritage, a city that once expanded its empire throughout Europe, Africa and Asia.Attractions of rome are Colosseum, St.Peter's Basilica, Pantheon, Vatican Museums, Trevi Fountain, Spanish Steps, Roman Forum, Castel Sant'Angelo, Piazza Navona, Campo de' Fiori, and many other renaissance architecture.
CBCR 2019 hosted by the Sciinov Group during September 02-03, 2019 at Rome, Italy got magnificent response.
CBCR 2019 is extremely well-known annual congress hosted by Sciinov Conferences which marked with the attendance of young and brilliant researchers, business delegates and talented student communities representing diverse countries around the world.
For CBCR 2019 Speakers Line-up: Click Here
Rockville, MD, May 15, 2019 MacroGenics Inc (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.....Read More
16 May 2019 Two cancer drugs have been approved for patients on the NHS in Scotland. An immunotherapy for some people with advanced skin cancer and a targeted drug for ,.....Read More
Rockville, MD, May 15, 2019 MacroGenics Inc (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal.....Read More
Eagan, MN - May 16, 2019 - Biothera Pharmaceuticals Inc which is developing a dectin receptor agonist drug known as Imprime PGG, announced today that it will present.....Read More
Rehovot, Israel, May 23, 2019 Todos Medical Ltd (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early .....Read More
23 May 201 Biocon Ltd and Mylan N.V. have announced that Health Canada has approved Mylan's Ogivri (trastuzumab), a biosimilar to Herceptin® (trastuzumab).....Read More
May 24, 2019 Irvine, Calif., U.S., and Amsterdam, Netharlands - 21 May 2019 - Agendia Inc a world leader in precision oncology, announced today an agreement .....Read More
Basel, May 24, 2019 - Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with .....Read More
